Retraction: The Tumor-Suppressive MicroRNA-135b Targets c-Myc in Osteoscarcoma (PLoS ONE (2014) 9:7 (e102621) DOI: 10.1371/journal.pone.0102621);The tumor-suppressive microRNA-135b targets c-Myc in osteoscarcoma

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Liu, Zheng ^a   Zhang, Guangwu ^a   Li, Jian ^a   Liu, Jiabang ^a   Lv, Pengfeng ^a  

^a PEKING UNIVERSITY SHOUGANG HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 135B; MYC PROTEIN; UNCLASSIFIED DRUG; MIRN135 MICRORNA, HUMAN; MYC PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL LINE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C MYC; OSTEOSARCOMA; PROTEIN DEGRADATION; PROTEIN RNA BINDING; RNA GENE; TISSUE DISTRIBUTION; ADOLESCENT; BONE TUMOR; CELL MOTION; CHILD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

ADOLESCENT; BASE SEQUENCE; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE;

EID: 84904255913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0282982     Document Type: Erratum

References (33)

1. Thayanithy V, Park C, Sarver AL, Kartha RV, Korpela DM, et al. (2012) Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One 7: e43720.
2. Yan K, Gao J, Yang T, Ma Q, Qiu X, et al. (2012) MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 7: e33778.
3. Wu X, Zhong D, Gao Q, Zhai W, Ding Z, et al. (2013) MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether a go-go 1 expression. Int J Med Sci 10: 676-682.
4. Zhao H, Guo M, Zhao G, Ma Q, Ma B, et al. (2012) miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med 30: 1013-1020.
5. Yang J, Zhang W (2013) New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 25: 398-406.
6. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, et al. (2011) MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 19: 1123-1130.
7. Zhou G, Shi X, Zhang J, Wu S, Zhao J (2013) MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res 41: 1-12.
8. Miao J, Wu S, Peng Z, Tania M, Zhang C (2013) MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol.
9. Zheng Y, Cui L, Sun W, Zhou H, Yuan X, et al. (2011) MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark 10: 71-77.
10. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, et al. (2009) MicroRNA profiling of human gastric cancer. Mol Med Report 2: 963-970.
11. Huang J (2009) Current progress in epigenetic research for hepatocarcinomagenesis. Sci China C Life Sci 52: 31-42.
12. Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, et al. (2013) miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. Am J Pathol 182: 2058-2070.
13. Khatri R, Subramanian S (2013) MicroRNA-135b and Its Circuitry Networks as Potential Therapeutic Targets in Colon Cancer. Front Oncol 3: 268.
14. Zhao L, Sun Y, Hou Y, Peng Q, Wang L, et al. (2012) MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer. Int J Biochem Cell Biol 44: 2051-2059.
15. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, et al. (2013) MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun 4: 1877.
16. Halappanavar S, Nikota J, Wu D, Williams A, Yauk CL, et al. (2013) IL-1 receptor regulates microRNA-135b expression in a negative feedback mechanism during cigarette smoke-induced inflammation. J Immunol 190: 3679-3686.
17. Zhang H, Zhang Y, Duan HO, Kirley SD, Lin SX, et al. (2008) TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer 123: 810-816. (Pubitemid 352032406)
18. Xu Y, Zhao F, Wang Z, Song Y, Luo Y, et al. (2012) MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene 31: 1398-1407.
19. Wu WY, Xue XY, Chen ZJ, Han SL, Huang YP, et al. (2011) Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. World J Gastroenterol 17: 3645-3651.
20. Tie J, Pan Y, Zhao L, Wu K, Liu J, et al. (2010) MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6: e1000879.
21. Schaap-Oziemlak AM, Raymakers RA, Bergevoet SM, Gilissen C, Jansen BJ, et al. (2010) MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells. Stem Cells Dev 19: 877-885.
22. Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, et al. (2013) Upregulation of miR-135b Is Involved in the Impaired Osteogenic Differentiation of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients. PLoS One 8: e79752.
23. Li Y, Liu H, Lai C, Du X, Su Z, et al. (2013) The Lin28/let-7a/c-Myc pathway plays a role in non-muscle invasive bladder cancer. Cell Tissue Res 354: 533-541.
24. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, et al. (2013) Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 34: 2823-2832.
25. Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, et al. (2013) Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res 19: 5798-5807.
26. Nair R, Roden DL, Teo WS, McFarland A, Junankar S, et al. (2013) c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene.
27. Li K, Chen MK, Situ J, Huang WT, Su ZL, et al. (2013) Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery. Chin Med J (Engl) 126: 82-87.
28. Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, et al. (2013) The IkappaB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol 5: 280-282.
29. Pello OM, Andres V (2013) Role of c-MYC in tumor-associated macrophages and cancer progression. Oncoimmunology 2: e22984.
30. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, et al. (1998) Cmyc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55: 556-563. (Pubitemid 28479115)
31. Wu X, Cai ZD, Lou LM, Zhu YB (2012) Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol 36: 212-216.
32. Shimizu T, Ishikawa T, Sugihara E, Kuninaka S, Miyamoto T, et al. (2010) c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 29: 5687-5699.
33. Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, et al. (2008) Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 19: 1500-1508.